– UK, London – Electrical Geodesics, Inc. (AIM: EGI:L), a leading neurodiagnostic medical technology company, today announces the appointment of Raymond Neal Englander, M.D. as a non-executive director with immediate effect.
Dr. Englander, aged 67, is a practicing neurologist with some 40 years experience in the field. He currently serves as the Medical Director of the Stroke Centre of the Sacred Heart Medical Centre in Oregon and recently stepped down as a Medical Informaticist for the Peace Health hospital group in the United States. He is a Clinical Instructor in the Department of Neurology School of Medicine at Oregon Health and Science University. Ray has served on the board of the medical malpractice insurers, Northwest Physicians Mutual Insurance Co., as President of the not-for-profit Lane County Medical Society and as an advisor to The Doctors Company Limited He is a Fellow of both the American Academy of Neurology and the American Heart Association.
Don Tucker, PhD, Chairman and CEO, commented: “Ray brings a wealth of experience of the practical applications of neurological technologies and techniques in the clinical and hospital setting in the US, together with a broad understanding of the administration of hospitals and reimbursement matters. His business experience in the management of medical insurance will bring a further level of governance to EGI and we look forward to his input to the Board and its audit and remuneration committees.”
About EGI
Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography (“dEEG”) platform technology. The Company’s technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.
EGI’s dEEG systems, available in the GES 300 and now the GES 400 lines, capitalize on the Company’s unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI’s technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI’s proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company’s products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).
About EGI’s ADAPT Amplifier Platform
The ADAPT technology includes on-board computing within the amplifier through an embedded processor, internal data storage, and wireless capabilities enabling remote software upgrades, greatly streamlining the delivery of new features to customers, and reducing the footprint required by the EEG system. In the future, the on-board computing capabilities will help enable a fully networked neuroscience laboratory or clinic, where autonomous acquisition and storage of EEG data can be linked and streamed directly to a secure network. Here, review stations will be able to monitor the data stream in real time and a common laboratory storage system can coordinate data acquisition from multiple units.
In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
